SCHEMBL439279

SCHEMBL439279

O=C(O)CSc1ncnc2c(C3CC3)c(Cl)sc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 17/20 1.00
STK17B O94768 2/20 0.51
MAP3K8 P41279 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30320288 1.00 NOTUM (1.00) NOTUMSTK17BMAP3K8
SCHEMBL16333308 0.86 NOTUM (0.76) NOTUM
SCHEMBL438084 0.85 NOTUM (1.00) NOTUMSTK17B
SCHEMBL440706 0.82 NOTUM (1.00) NOTUMSTK17BMAP3K8
SCHEMBL441103 0.80 NOTUM (1.00) NOTUMSTK17BMAP3K8
SCHEMBL16333303 0.78 NOTUM (0.74) NOTUMSTK17BMAP3K8
SCHEMBL441163 0.75 NOTUM (0.59) NOTUM
SCHEMBL16333597 0.74 NOTUM (1.00) NOTUMSTK17BMAP3K8
SCHEMBL438085 0.73 NOTUM (0.77) NOTUMMAP3K8
SCHEMBL439282 0.73 NOTUM (0.56) NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092358-A1 In Vitro Breeding Systems and Methods in Livestock ABS GLOBAL, INC. (US) 2025-03-20 US claimed
EP-4493275-A1 METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS Memorial Sloan Kettering Cancer Center (US) 2025-01-22 EP claimed
US-20250017979-A1 METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2025-01-16 US claimed
US-20240279601-A1 METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2024-08-22 US claimed
EP-4355864-A1 METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF Memorial Sloan Kettering Cancer Center (US) 2024-04-24 EP claimed
EP-4346395-A1 IN VITRO BREEDING SYSTEMS AND METHODS IN LIVESTOCK ABS Global, Inc. (US) 2024-04-10 EP claimed
US-20240091254-A1 WNT AGONISTS FOR PREVENTION OF CANCER Stichting Amsterdam UMC (NL) 2024-03-21 US claimed
EP-4322986-A1 WNT AGONISTS FOR PREVENTION OF CANCER Academisch Medisch Centrum (NL) 2024-02-21 EP claimed
CN-117412668-A Livestock in vitro breeding system and method ABS全球公司 2024-01-16 CN claimed
WO-2023177919-A1 METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2023-09-21 WO claimed
CN-115768875-A Method for producing mesocerebral dopamine neurons, mesocerebral neurons and uses thereof 纪念斯隆-凯特琳癌症中心 2023-03-07 CN claimed
EP-4127137-A1 METHODS OF GENERATING MIDBRAIN DOPAMINE NEURONS, MIDBRAIN NEURONS AND USES THEREOF Memorial Sloan Kettering Cancer Center (US) 2023-02-08 EP claimed
WO-2022266527-A1 METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2022-12-22 WO claimed
WO-2022251549-A1 IN VITRO BREEDING SYSTEMS AND METHODS IN LIVESTOCK ABS GLOBAL, INC. (US) 2022-12-01 WO claimed
WO-2022219004-A1 WNT AGONISTS FOR PREVENTION OF CANCER ACADEMISCH MEDISCH CENTRUM (NL) 2022-10-20 WO claimed
EP-2616471-B1 INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS INC (US) 2014-12-31 EP claimed
US-20140288071-A1 INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE BARBOSA JOSEPH (US) 2014-09-25 US claimed
EP-2616471-A1 INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE Lexicon Pharmaceuticals, Inc. (US) 2013-07-24 EP claimed
WO-2012037141-A1 INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS, INC. (US) 2012-03-22 WO claimed
US-20120065200-A1 INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS, INC. 2012-03-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065200-A1 INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE NOTUM, GLA, CES1 NOTUM 1/4885STK17B 4180/4885MAP3K8 2640/4885
US-20240279601-A1 METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF CHAT, ALPG, GFRA3 NOTUM 3841/4885STK17B 2581/4885MAP3K8 2242/4885
US-20140288071-A1 INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE NOTUM, GLA, CES1 NOTUM 1/4885STK17B 4180/4885MAP3K8 2640/4885
US-20250017979-A1 METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS CHAT, PINK1, DBH NOTUM 4383/4885STK17B 1491/4885MAP3K8 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.